Clinical Trials Arena March 4, 2024
Abigail Beaney

The study looked at medical records of more than three million diabetic patients and almost one million non-diabetic patients.

A study claims that there is a link between weight-loss drugs and a reduced risk of depression and anxiety.

The study, which reviewed the medical records of over three million diabetic patients and almost one million non-diabetic patients, found that patients prescribed glucagon such as peptide-1 receptor agonists (GLP1-RA) medications such as Wegovy and Mounjaro were less likely to be diagnosed with depression and anxiety.

GLP1-RA drugs have taken the type 2 diabetes and obesity market by storm with market leaders Novo Nordisk and Eli Lilly becoming the two biggest pharmaceutical companies in the world. As a result, the candidates are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mental Health, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article